Diabetes prevention project coordinated by Diamyd Medical to be presented at scientific conference

The ASSET (AI for Sustainable Prevention of Autoimmunity in the Society) innovation milieu for the development of improved prevention strategies in Type 1 Diabetes, funded by the Swedish innovation agency VINNOVA, will be presented by PhD Ulf Hannelius, CEO of Diamyd Medical, at the Annual Meeting of the Scandinavian Society for the Study of Diabetes (SSSD), to be held in Reykjavík on May 12-13, 2022. The presentation will be given under the title “ASSET- a public/private partnership developing an integrated approach to prevention of Type 1 Diabetes (T1D)”.

Diamyd Medical and five other public and private entities were awarded SEK 40 million by VINNOVA in September 2021 for a five-year project aimed at establishing a multi-stakeholder, interdisciplinary innovation millieu. The grant is one of the largest grants ever awarded for the study of Type 1 Diabetes (T1D) in Sweden and the project is one of the most ambitious efforts ever launched in Scandinavia to develop, test and potentially implement screening and prevention for the disease. The innovation milieu will develop and evaluate new algorithms based on artificial intelligence (AI) as a tool in precision health. The project will initially focus on improving assessment of the individual risk of developing Type 1 Diabetes and the likelihood of responding to different treatments. The other entities in the consortium are the privacy pereserving AI solutions-focused company MainlyAI, Lund University, Sahlgrenska University Hospital, The Swedish National Diabetes Registerand The Leading Health Care Foundation.

The 56th Annual Meeting of SSSD will be held in Reykjavik, Iceland, on May 12-13, 2022. Program and registration details can be found on https://www.sssd2022.is

The innovation milieu ASSET (AI for Sustainable Prevention of Autoimmunity in the Society) will develop and evaluate new algorithms based on AI to be able to assess the individual risk of developing Type 1 Diabetes (T1D), and the likelihood of responding to different treatments. Data from cohort studies such as TEDDY (The Environmental Determinants of Diabetes in the Young), from Diamyd Medical's clinical trials with Diamyd® and from sources such as the National Diabetes Registry will consitute the initial training dataset for the algorithm. T1D will form the pilot project for the program, but the goal is extend the functionality to other indications including other autoimmune diseases that are strongly linked to T1D such as celiac disease (gluten intolerance) and autoimmune thyroiditis (inflammatory disease of the thyroid gland). The prediction algorithm will be evaluated in clinical prevention trials where individuals at high risk for type 1 diabetes will be treated preventively with the diabetes vaccine Diamyd®. In parallel, ASSET will study organizational, economic, and legal prerequisites and consequences of applying the approach as a tool for precision health in the Swedish health care system. The project has a duration of five years and is financed via the Swedish innovation agency VINNOVA.

The ASSET consortium consists of Mainly AI, Lund University, Sahlgrenska University Hospital, The Swedish National Diabetes Register, Leading Health Care Foundation and Diamyd Medical (project coordinator).

About Diamyd Medical
Diamyd Medical develops precision medicine therapies for type 1 diabetes. The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. DIAGNODE-3, a confirmatory Phase III trial is on-going. A vaccine manufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in individuals living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.

Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

The information was provided by the contact person above, for publication on March 28, 2022, 11.30 CET.


  PDF version